Regulatory modifiers of coding variant penetrance via haplotype epistasis in human populations and diseases

Information

  • Research Project
  • 9691927
  • ApplicationId
    9691927
  • Core Project Number
    R01GM122924
  • Full Project Number
    5R01GM122924-03
  • Serial Number
    122924
  • FOA Number
    PA-16-160
  • Sub Project Id
  • Project Start Date
    5/1/2017 - 7 years ago
  • Project End Date
    4/30/2022 - 2 years ago
  • Program Officer Name
    JANES, DANIEL E
  • Budget Start Date
    5/1/2019 - 5 years ago
  • Budget End Date
    4/30/2020 - 4 years ago
  • Fiscal Year
    2019
  • Support Year
    03
  • Suffix
  • Award Notice Date
    5/7/2019 - 5 years ago

Regulatory modifiers of coding variant penetrance via haplotype epistasis in human populations and diseases

PROJECT ABSTRACT Variable penetrance is a phenomenon where the severity of the effect of a genetic variant differs among individuals who carry it. We propose to study a specific type of modified penetrance caused by genetic interaction or epistasis in humans, where a regulatory variant in cis modifies the penetrance of coding variants of the target gene. We call this phenomenon haplotype epistasis. We will study this phenomenon using genetic data of the general human population and of diseases with different genetic architectures. First, we will study signals of purifying selection against specific haplotype combinations as a proxy of phenotypically relevant epistatic effects. This will shed light on the modes and prevalence of haplotype epistasis, and the role of epistatic selection in shaping the spectrum of genetic variation in humans. Second, haplotype epistasis has been shown to affect genetic disease risk in some specific examples, but this mechanism is rarely considered in genetic studies that typically analyze genetic variants one-by-one. We aim to characterize haplotype epistasis as a potentially important phenomenon in rare variants contributing to autism risk, common variants predisposing to diverse traits mapped by genome-wide association studies, and germline modifiers of somatic cancer driver mutations. Furthermore, we will validate 5-10 examples of epistasis by genome editing of human cell lines, followed by cellular phenotyping. In summary, our study integrates many domains in human genetics that are usually studied in isolation. It is the first systematic characterization of haplotype epistasis and has potential to bring forward an important paradigm of epistatic functional effects of genetic variants.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R01
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
    243124
  • Indirect Cost Amount
    126042
  • Total Cost
    369166
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:369166\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    GVE
  • Study Section Name
    Genetic Variation and Evolution Study Section
  • Organization Name
    NEW YORK GENOME CENTER
  • Organization Department
  • Organization DUNS
    078473711
  • Organization City
    NEW YORK
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    100131941
  • Organization District
    UNITED STATES